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Abstract
Background: Leptospirosis is a re-emerging bacterial zoonosis caused by spirochetes of the genus Leptospira.
Severe disease has been reported in dogs in Europe despite vaccination with bivalent Leptospira vaccines. Recently,
a tetravalent canine Leptospira vaccine (Nobivac® L4) was licenced in Europe. The goal of this study was to
investigate clinical signs, microscopic agglutination test (MAT) titres, haematology, blood biochemistry, cardiac
(c) Troponin I levels and echocardiography before and after vaccination with this tetravalent vaccine. Forty-eight
healthy dogs were prospectively enrolled and vaccinated twice, 3–4 weeks apart (T0 and T1). Before vaccination
(T0) and 16–31 days after the second vaccination (T2), MAT (n = 48), haematology (n = 48), blood biochemistry
(n = 36) and cTroponin I measurements (n = 29) were performed, and MAT was repeated 347–413 days after the
second vaccination (T3, n = 44). Echocardiography was performed before the first and second vaccination (T0 and
T1, n = 24).
Results: Mild and transient clinical signs within 5 days following the first and second vaccination occurred in 23%
and 10% of the dogs, respectively. Before the first vaccination (T0), all dogs showed negative MAT titres for the
tested serovars except for Canicola (50% with titres 100–400). At T2, positive MAT titres to the serovars Canicola
(100%), Australis (89%), Grippotyphosa (86%), Bratislava (60%), Autumnalis (58%), Copenhageni (42%), Pomona
(12%), Pyrogenes (8%) and Icterohaemorrhagiae (2%) were found. Median to high titres (≥ 400) were most
common to the serovar Canicola (92%) and less common to the serovars Australis (41%), Grippotyphosa (21%),
Bratislava (12%), Autumnalis (4%), Pyrogenes (4%) and Pomona (2%). At T3, positive MAT titres (titre range: 100–
400) were found in 2–18% of the dogs to serovars of the vaccine serogroups and in 2–18% of the dogs to the
non-vaccine serovars Pomona, Autumnalis, Pyrogenes and Ballum. Haematology, blood biochemistry, cTroponin I
levels and echocardiography results did not change significantly following vaccination.
Conclusions: Clinical signs following vaccination with Nobivac® L4 were transient and mild in all cases. Seroconversion
differed considerably among individual dogs and among the vaccine serogroups.
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Background
Leptospirosis is a re-emerging bacterial zoonosis of glo-
bal importance caused by spirochetes of the genus Lep-
tospira [1]. Dogs can be infected with a wide range of
pathogenic Leptospira serovars and shed the leptospires
in their urine during acute infection [2]. Leptospires
can survive for months in water and moist soil [3], and
indirect transmission through contact with contami-
nated soil or water is thought to play an important role
in the epidemiology of leptospirosis.
In Europe, canine leptospirosis in dogs has gained in-
creasing attention in the last several years [4]. Following
infection with pathogenic leptospires, dogs can develop
a severe, multi-systemic disease associated with high
mortality [2]. Besides this severe course of infection,
mild clinical signs and asymptomatic infections have
been documented. Acute leptospirosis in dogs is mainly
associated with acute kidney or liver injury and respira-
tory signs associated with pulmonary haemorrhage [5].
Furthermore, myocarditis has been documented in
humans with leptospirosis and has also been suspected
in infected dogs [6, 7]. The clinical manifestation of
leptospirosis depends not only on the causative serovar
but also on host-specific factors such as age and the
immune status of the dog [8].
The most commonly used diagnostic test for leptospir-
osis in dogs is the demonstration of antibodies in the
microscopic agglutination test (MAT). Serial dilutions of
patient sera are thereby incubated with a selection of
pathogenic Leptospira serovars, and agglutination of the
organisms is assessed by darkfield microscopy. Cross-
reactivity among serovars only allows for a serogroup-
specific diagnosis, and positive titres following vaccination,
previous exposure and during chronic asymptomatic in-
fection complicate the interpretation of the results [2].
Generally, the serovar that gives the highest titre is
regarded as the infecting serogroup or serovar, although
this diagnosis is, at best, presumptive [9]. Post-vaccination
titres have been assessed in small groups of dogs following
vaccination with bivalent and tetravalent vaccines [10–12].
These studies revealed that titres usually decline by
4 months after vaccination, although persistently high
titres have been documented which have been ex-
plained by natural exposure to Leptospira field serovars
[10]. PCR can be used as an alternative diagnostic
method to detect leptospiral DNA in biological samples
such as blood, urine or tissue. However, leptospires can
only transiently be detected in the blood and urine of
infected animals [13], and antibiotic therapy is thought
to clear bacteraemia and leptospiruria [14]. The detec-
tion of the agents in biological samples by bacterial cul-
ture is a definitive proof of infection [2], but leptospires
are fastidious organisms requiring special culture
media, and they grow very slowly after 2 to up to
24 weeks in culture, making this diagnostic procedure
impractical in a clinical setting.
Despite the introduction of efficient bivalent Leptospira
bacterin vaccines some decades ago [15], clinical lepto-
spirosis has recently been documented among numerous
vaccinated dogs in Europe [16]. The currently licenced
bivalent Leptospira vaccines in Europe contain serovars
belonging to the serogroups Canicola and Icterohaemor-
rhagiae. These vaccines have been shown to prevent
leptospirosis caused by serovars belonging to these two
serogroups, but the vaccines induce only partial or no
immunity to heterologous serogroups [17–19]. Canicola
and Icterohaemorrhagiae were previously thought to be
the main serogroups causing clinical leptospirosis in
dogs. Recent seroepidemiological studies revealed, how-
ever, that dogs are susceptible to a broad range of serovars.
In Europe, antibodies against the serogroups Icterohae-
morrhagiae, Canicola, Grippotyphosa, Pomona, Australis
and Sejroe have most commonly been documented in
clinically healthy and diseased dogs [4].
In 2012, a new canine tetravalent inactivated Leptospira
vaccine (Nobivac® L4, in Switzerland licenced as Nobivac®
Lepto 6, MSD Animal Health GmbH, Luzern, Switzerland)
that contains antigens from serovars from four different
serogroups, including Canicola, Icterohaemorrhagiae,
Australis and Grippotyphosa was licenced in Europe
[20, 21]. Because serology represents the mainstay in the
diagnosis of leptospirosis in dogs, the serological response
following vaccination can interfere with the interpretation
of MAT results in suspect clinical cases [22]. So far, no
data on the serological response following vaccination
with this novel tetravalent vaccine have been published.
Furthermore, recent pharmacovigilance reports from
Germany and Switzerland suggest that adverse events
after vaccination with Leptospira vaccines have signifi-
cantly increased since 2013 and 2014, respectively, follow-
ing the introduction of novel, multivalent Leptospira
vaccines in these countries [23, 24]. The authors of the re-
ports speculated that the increasing number of Leptospira
serovars included in these vaccines could result in higher
antigenicity of the vaccines. However, studies investigating
the incidence of adverse events following the vaccination
of dogs did not reveal a significant increase in hypersensi-
tivity reactions following Leptospira vaccination when
compared with other vaccines [25, 26]. Finally, there have
been recent anecdotal reports describing cardiac abnor-
malities suspicious of acute myocarditis after vaccination
(S. Jenni, personal communication). Specifically, at the
second vaccination, new heart murmurs had been auscul-
tated that had not been present at the first vaccination.
Subsequent echocardiographic examinations reportedly
had revealed left ventricular dilation and hypocontractility
with mitral annulus dilation and associated mitral insuffi-
ciency as the explanation for the murmur.
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The goal of the present study was to evaluate the sero-
logical response of dogs after vaccination with a commer-
cially available, inactivated, tetravalent Leptospira vaccine
and to investigate whether the dogs showed clinical signs
and alterations in haematology, blood biochemistry and
echocardiography following vaccination.
Methods
Study design, sample and data collection and sample
processing
This monocentric, longitudinal, prospective study was
performed at the Clinic for Small Animal Internal
Medicine, University of Zurich, between August 2013
and May 2015. Dogs were prospectively enrolled within
the study when they met the following inclusion cri-
teria: older than 8 weeks of age, judged clinically
healthy by the owner, in good general health according
to clinical examination, no vaccination within 4 weeks
and no medical therapy within 2 months prior to study
enrolment, with the exception of antiparasitic treat-
ment. The study design and number of dogs that re-
ceived each procedure are shown in Table 1. The day of
the first vaccination was defined as T0. All dogs were
vaccinated twice with a commercial tetravalent lepto-
spirosis vaccine (Nobivac® L4, in Switzerland licenced
as Nobivac® Lepto 6, MSD Animal Health GmbH) 3–
4 weeks apart (T0 and T1). Additional vaccine compo-
nents licenced for concurrent administration were ap-
plied as required (Table 1). Blood samples were collected
by venipuncture before the first (T0) and second vaccin-
ation (T1) and 41–54 days (T2) and 368–434 days after
the first vaccination (T3). Blood samples were processed
or frozen at −80 °C within 4 h of collection. A medical
history and clinical examination were performed at each
presentation by a veterinary surgeon (AS) or a board-
certified internal medicine specialist (BW). Echocardiog-
raphy was performed before the first (T0) and second
vaccination (T1) by board-certified cardiologists (JM,
TG) at the division of cardiology, Vetsuisse Faculty, Uni-
versity of Zurich. Adverse vaccine events were suspected
when clinical signs occurred within 5 days of vaccination
and belonged to one of the following groups: lethargy or
inappetence, local reaction at the injection site (signs of
tenderness or pain, cutaneous swelling or mass, lame-
ness in a limb close to the injection site), non-specific
signs (periuria, diarrhoea, vomiting) or a hypersensitivity
reaction (swelling of the face, hives or bumps on the face
or body, hypersalivation, tachypnoea, or respiratory dis-
tress). Data on adverse vaccine events were collected
from the medical history and clinical examination per-
formed at each presentation.
Haematology, blood biochemistry and cTroponin I
Haematology and blood biochemistry tests and mea-
surements of cTroponin I were performed at the Clin-
ical Laboratory, Vetsuisse Faculty, University of Zurich.
Haematology was performed from EDTA anti-
coagulated whole blood within 4 h of sample collection.
Blood biochemistry was determined batch-wise from
serum samples stored at −80 °C. Haematology and blood
biochemistry were run on a Sysmex XT-2000iV (Sysmex
Corporation, Kobe, Japan) [27] and Cobas Integra 800 in-
strument (Roche Diagnostics AG, Rotkreuz, Switzerland),
respectively. The clinical chemistry parameters included:
albumin, total protein, alanine aminotransferase (ALAT),
alkaline phosphatase (AP), bilirubin, urea, creatinine and
lipase. The laboratory’s device-specific reference intervals
were applied. cTroponin I was measured on an Immulite
1000 (Siemens Healthcare Diagnostics GmbH, Zurich,
Switzerland). The serum cTroponin I concentration was
measured using a commercially available assay that had
been validated for the dog [28]. The test’s lower limit of
detection was 0.2 ng/mL, and cTroponin I values exceed-
ing 0.2 ng/mL were considered increased.
Table 1 Study design and number of dogs that received each procedure
Time point T0 T1 T2 T3
Days after first presentation 0 20–28 41–54 368–434
Procedure/number of dogs
Vaccination 48 48 - 44
Clinical examination 48 48 48 44
Echocardiography 24 24 - -
MAT 48 - 48 44
Haematology 48 - 48 -
Blood biochemistry 36 - 36 -
cTroponin I 29 - 29 -
Number of dogs receiving other vaccine components
Nobivac® DHPPi 16 3 - -
Nobivac® Pi 10 1 - -
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Microscopic agglutination test
The MAT was performed at the National Reference La-
boratory for animal leptospirosis at the Institute of Vet-
erinary Bacteriology, Vetsuisse Faculty, University of
Bern, Switzerland. The MAT was performed batch-wise
from serum samples stored at −80 °C that were sent by
priority mail at room temperature to the laboratory.
Samples were examined for the presence of antibodies
against a standard panel of 14 pathogenic Leptospira
strains commonly used in Switzerland (Table 2) by
MAT according to Office International des Epizooties
(OIE) standards [29]. To prevent inter-observer vari-
ability, all samples were tested by the same person. The
end-point titre refers to the reciprocal of the highest
serum dilution at which at least 50% agglutination
occurs. In this study, sera with a titre of 100, indicating
past exposure to Leptospira [8], were considered
seropositive.
Echocardiography
Echocardiographic examinations were performed with
continuous ECG monitoring on laterally recumbent
unsedated dogs using a GE Vivid 7 ultrasound unit
(Vivid 7, GE Medical Systems, Munich, Germany).
Standard two-dimensional, M-mode and colour Doppler
echocardiographic views were obtained from standard
right parasternal views using a 7 MHz transducer. The
primary focus was qualitative left ventricular size and
function as well as valvular integrity and function. Quan-
titated parameters were left ventricular diameter in dia-
stole and systole (LVDd and LVDs, respectively), the
shortening fraction (%FS) from M-Mode images, and the
left atrial to aortic ratio (LA/Ao) in short axis [30, 31].
Statistical analyses
Statistical analyses were performed using Analyse-it® for
Microsoft Excel version 1.0.5.0 (Analyse-it Software,
Ltd., Leeds, United Kingdom) and GraphPad Prism 5.03
(GraphPad Software, Inc., CA, USA). The Wilcoxon
signed rank test (pw) was used to compare the results
from the same dog at two different time points. Cor-
relation between MAT titres and time elapsed since
the last Leptospira vaccination was assessed using the
Spearman rank correlation test (correlation coeffi-
cient: rsp). Proportions between groups were analysed
with the Fisher’s exact test (pF). P-values <0.05 were
considered significant.
Results
Characteristics of the study population
A total of 48 dogs were included in the study. The
characteristics of the study population are shown in
Table 3. All but one dog had previously received a Lep-
tospira vaccine; all vaccine products were inactivated
bivalent Leptospira vaccines containing serovars from
the serogroups Canicola and Icterohaemorrhagiae. The
vaccines belonged to several different brands (Canigen®
L (n = 28), Canigen® 7 (n = 1), Virbac, Glattbrugg,
Switzerland; Canimed® L (n = 1), Eurican® L (n = 1),
Merial, Lyon, France; Nobivac® Lepto (n = 8), Vetamun®
Lepto (n = 6), MSD Animal Health GmbH; Vanguard®
7 (n = 2), Zoetis Schweiz GmbH, Zurich, Switzerland).
All 48 dogs completed the primary vaccination schedule,
and 44 dogs were sampled after 1 year (T3, Table 1);
the remaining four dogs died within 1 year after vaccin-
ation for unrelated reasons (n = 2), moved to another
country (n = 1) or did not keep the appointment after
Table 2 The 14 Leptospira spp. strains used as live antigens in the microscopic agglutination testa
Genomospecies Serogroup Serovar Strain
Leptospira interrogans Australis Australis Ballico
Australis Bratislava Jez-Bratislava
Autumnalis Autumnalis Akiyami
Bataviae Bataviae Swart
Canicola Canicola Hond Utrecht IV
Icterohaemorrhagiae Icterohaemorrhagiae RGA
Icterohaemorrhagiae Copenhageni M20
Pomona Pomona Pomona
Pyrogenes Pyrogenes Salinem
Sejroe Hardjo Hardjoprajitno
Leptospira borgpetersenii Ballum Ballum Mus127
Tarassovi Tarassovi Perepelitsin
Sejroe Sejroe M84
Leptospira kirschneri Grippotyphosa Grippotyphosa Moskva V
aAll reference strains were obtained from the Royal Tropical Institute (KIT), Amsterdam, The Netherlands
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1 year (n = 1). The two dogs that died were 11 and
14 years old and were euthanized because of histiocytic
sarcoma or acute monoparesis that occurred 137 and
340 days after the second vaccination, respectively.
Clinical examination
Clinical examination was unremarkable in 75–90% of
the dogs at each presentation (Additional file 1). Clin-
ical findings included vaginal discharge due to juvenile
vaginitis or heat, conjunctivitis, faint heart murmurs,
splenomegaly, focal pyoderma, inflammation or fistula
in the anal region, red and scaly ears, fluid-filled
bowel loops, enlarged prostate and depigmentation
of the nose.
Following the first and second vaccination, adverse
vaccine events were reported by the owners of 11 (23%)
and 5 (10%) dogs, respectively (Additional file 1). The
clinical signs occurred within 5 days of vaccination and
were transient and mild in all cases. The clinical signs
mainly included local reactions at the injection site,
lethargy or inappetence. Three dogs showed a single
episode of vomiting or periuria. A total of 6 out of 11
dogs with adverse events after the first vaccination had
received additional vaccine components (Nobivac® DHPPi,
n = 3, Nobivac® Pi, n = 3). None of the five dogs with ad-
verse events after the second vaccination had received
additional vaccine components. The proportion of animals
that showed adverse vaccine events was not significantly
different between dogs that had or had not received add-
itional vaccine components (pF = 1.0). Other anamnestic
abnormalities that occurred after 5 days of vaccination
were reported in 5 (10%) and 4 (8%) dogs after the
first (T0) and second vaccination (T1), respectively.
They included a single episode of vomiting or diar-
rhoea 10–14 days after vaccination, a depigmentation
of the planum nasale that started 7 days after vaccin-
ation, acute trembling and a focal epileptic seizure 3
and 4 weeks after vaccination, respectively, coughing
3 weeks after vaccination, a reduced general condition
10 days after vaccination and tenesmus due to pros-
tate enlargement 3 weeks after vaccination. At the
time of the 1-year booster vaccination (T3), two dogs
had died (see above), one dog had developed laryn-
geal paralysis, one dog suffered from idiopathic epi-
lepsy and one dog had developed and recovered from
an acute encephalitis.
Table 3 Characteristics of the 48 dogs of this study
Parameter Number of dogs Range Median 95% CIa
Age (years) 48 0.4–14 5 4.2–6.3
Body weight (kg) 48 5.5–51.2 21 18.0–25.1
Days to prior leptospirosis vaccination 47 31–1745 379 386.5–640.5
Parameter Number of dogs (%)
Gender
Female intact 16 (33)
Female castrated 16 (33)
Male intact 14 (29)
Male castrated 2 (4)
Pedigree
Yes 39 (81)
No 9 (19)
Breed
Barzoi 8 (17)
Beagle 4 (8)
Labrador Retriever 5 (10)
Jack Russel Terrier 2 (4)
Rhodesian Ridgeback 2 (4)
Shetland Sheepdog 6 (13)
Malinois 2 (4)
Whippet 2 (4)
Other breedsb 8 (17)
aCI, confidence interval
bOther breeds comprised: Old German Shepherd Dog, Australian Kelpie, Bavarian Mountain Hound, Golden Retriever, German Wirehaired Pointer, Small
Munsterlander, Poitevin, Schipperke (each n = 1)
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Microscopic agglutination test
MAT results for the 14 tested serovars are shown in
Table 4 for the serogroups included in the vaccine and
in Table 5 for the serogroups that are not included in
the vaccine. At first presentation and before the first
vaccination (T0), all dogs had negative MAT titres (< 100)
for all tested serovars, except for the serovar Canicola,
for which 50% of the dogs showed titres ≥100 at T0
(Table 4). All of the seropositive dogs had been previ-
ously vaccinated with a vaccine that contained a serovar
of the serogroup Canicola. In the 20 dogs with titres of
100, the previous Leptospira vaccine had been given
101–1745 days prior to study enrolment. In the three
dogs with titres of 200, the leptospirosis vaccine had
been given 176–554 days prior to study enrolment, and
in the one dog with a titre of 400, the vaccine had been
given 129 days before enrolment. There was no signifi-
cant correlation between the MAT titres to the serovar
Canicola and the time elapsed since the last vaccination
(rsp = − 0.006).
Positive MAT titres (≥ 100) measured after the second
vaccination (T2) were most common for the serovar
Canicola (100%), followed by the serovars Australis (89%),
Grippotyphosa (86%), Bratislava (60%), Autumnalis (58%),
Copenhageni (42%), Pomona (12%), Pyrogenes (8%) and
Icterohaemorrhagiae (2%, Tables 4 and 5). Median to high
titres (≥ 400) were most commonly found for the serovar
Canicola (92%), followed by the serovars Australis (41%),
Grippotyphosa (21%), Bratislava (12%), Autumnalis (4%),
Pyrogenes (4%) and Pomona (2%); none of the dogs devel-
oped titres ≥400 for the serovars Copenhageni or Ictero-
haemorrhagiae. Maximal MAT titres measured at T2 for
the serovars were as follows: Canicola (3200), Australis
(3200), Grippotyphosa (800), Bratislava (800), Autumnalis
(3200), Copenhageni (200), Pomona (400), Pyrogenes
(800) and Icterohaemorrhagiae (100).
At the 1-year booster appointment (T3), 2–18% of the
dogs showed positive MAT titres to serovars of the vaccine
serogroups, and the titres were generally low (< 400, Table
4). A total of 2–18% of the dogs showed positive MAT
titres to the non-vaccine serovars Pomona, Autumnalis,
Pyrogenes and Ballum (Table 5). The seven dogs with an
MAT titre of 400 against the serovar Pyrogenes at T3 had
negative titres against the other tested serovars at this time
point and had also been seronegative for the serovar Pyro-
genes following the second vaccination (T2). Positive MAT
titres were not detected at any time point during the study
for L. interrogans serovar Bataviae or for L. borgpetersenii
serovars Tarassovi, Hardjo and Sejroe (data not shown).
Haematology, blood biochemistry and cTroponin I
The haematological parameters determined before (T0)
and after the second vaccination (T2) revealed no signifi-
cant differences, with the exception of a slight but signifi-
cant increase in haematocrit (pW = 0.02) and a decrease in
total monocyte count at T2 compared to T0 (pW = 0.04;
Additional file 2). For the blood biochemistry results, sig-
nificant differences between T0 and T2 were only evident
for the AP activity (decrease; pW = 0.04) and the urea con-
centration (increase; pW = 0.03; Additional file 3). These
differences were small, and the median AP activity and
urea concentration remained within the reference range at
both time points. The cTroponin I concentrations were
obtained in 29 dogs. At T0, cTroponin I concentrations
were below the detection limit in 27 dogs; two dogs (both
Barzois) had measurable cTroponin I levels of 0.39 and
0.50 ng/mL. At T2, cTroponin I concentrations were
below the detection limit in 27 dogs; two dogs (both
Barzois) had measurable cTroponin I levels of 0.23 and
0.29 ng/mL; both dogs had had undetectable values at T0.
There was no significant difference between the cTroponin I
levels at T0 and T2.
Table 4 Microscopic agglutination test results for the vaccine serogroups before and after vaccination
Species L. interrogans L. interrogans L. interrogans L. interrogans L. interrogans L. kirschneri
Serogroup Canicola Icterohaemorrhagiae Icterohaemorrhagiae Australis Australis Grippotyphosa
Serovar Canicola Copenhageni Icterohaemorrhagiae Bratislava Australis Grippotyphosa
Time point T0 T2 T3 T0 T2 T3 T0 T2 T3 T0 T2 T3 T0 T2 T3 T0 T2 T3
Percentage of dogs with titre
< 100 50 0 91 100 58 95 100 98 98 100 40 98 100 11 82 100 14 95
100 42 2 9 0 33 5 0 2 2 0 19 0 0 27 11 0 42 5
200 6 6 0 0 9 0 0 0 0 0 29 2 0 21 7 0 23 0
400 2 34 0 0 0 0 0 0 0 0 10 0 0 25 0 0 19 0
800 0 29 0 0 0 0 0 0 0 0 2 0 0 8 0 0 2 0
1600 0 27 0 0 0 0 0 0 0 0 0 0 0 6 0 0 0 0
3200 0 2 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0
Total number of dogs 48 48 44 48 48 44 48 48 44 48 48 44 48 48 44 48 48 44
Positive titres are shown in bold
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Echocardiography
Left ventricular (LVDd) and left atrial (LA/Ao) size did
not significantly change between the first (T0) and the
second (T1) vaccination, and mitral insufficiency could
not be documented in any dog. Additionally, systolic
function, as assessed by LVDs and %FS, did not change
significantly between T0 and T1. Looking at individual
dogs, there was not any dog that showed a notable in-
crease in LVDd or LVDs. In none of the dogs could
any arrhythmia be recognized at any time point during
the study.
Discussion
This is the first independent study evaluating the sero-
logical and clinical response in field dogs following vac-
cination with a novel tetravalent Leptospira vaccine. Our
results suggest that the vaccine was generally well tolerated
and that there was marked variation among individual dogs
and among different vaccine serovars regarding the extent
of seroconversion following vaccination.
Up to 23% of the dogs in this study showed clinical
signs following vaccination, but they were mild and tran-
sient in all cases and did not include anaphylactoid reac-
tions. Leptospira vaccines have been said to carry an
increased risk of adverse events in puppies younger than
12 weeks of age and in small-breed dogs [32], but a recent
study evaluating the incidence rate of owner-reported
post-vaccination adverse events found no significant in-
crease in hypersensitivity reactions in dogs vaccinated
against Leptospira compared with other vaccines [25]. In
the present study, most of the adverse vaccine events
included discomfort at the injection site and transient
lethargy and inappetence. These are common clinical
signs induced by vaccination and have also been reported
for other vaccine products [33]. Because additional vac-
cine components were administered in six of the eleven
dogs that showed clinical signs after the first vaccination,
the clinical signs could also have been attributable to other
vaccine components. However, there was no significant
difference in the frequency of adverse events between dogs
that did or did not receive other vaccine components at
the first or second vaccination. In this study, we decided
to administer additional vaccine components as indicated
to mimic the situation in the field, where Leptospira
vaccines are usually administered together with other
vaccine components registered for concurrent applica-
tion. In light of the high incidence and mortality rate of
clinical leptospirosis in dogs in Europe [4, 5, 16], the
benefit of vaccinating dogs with this novel tetravalent
vaccine highly outweighs the risk of adverse events fol-
lowing vaccination.
The highest MAT titres after vaccination for the tested
serovars were observed for the serovars Canicola, Austra-
lis, Grippotyphosa, Bratislava and Autumnalis; the MAT
titres were generally low (up to 200) for the vaccine sero-
var Copenhageni (serogroup Icterohaemorrhagiae), with
only 42% of the study population showing positive titres
after the second vaccination. One recent study evaluated
vaccine-associated Leptospira antibodies in client-owned
dogs following vaccination with four different tetravalent
Leptospira vaccines (all containing the serovars Canicola,
Grippotyphosa, Icterohaemorrhagiae and Pomona) [10].
The authors found a comparable percentage of dogs with
positive titres for the serovars Canicola (100%), Grippoty-
phosa (72%) and Bratislava (44%) after vaccination as in
the present study, but in contrast to our results, 94% of
the dogs developed positive titres to the serovar Icterohae-
morrhagiae. The four vaccines tested in the previous study
were different from the vaccine used in the present study;
different vaccines could vary in their potential to induce
seroconversion to vaccine serovars depending on the
strains used in the vaccines. Alternatively, natural
Table 5 Microscopic agglutination test results for selected non-vaccine serogroups before and after vaccination
Species L. interrogans L. interrogans L. interrogans L. borgpetersenii
Serogroup Pomona Autumnalis Pyrogenes Ballum
Serovar Pomona Autumnalis Pyrogenes Ballum
Time point T0 T2 T3 T0 T2 T3 T0 T2 T3 T0 T2 T3
Percentage of dogs with titre
< 100 100 88 87 100 42 95 100 92 82 100 100 98
100 0 8 9 0 50 5 0 4 2 0 0 2
200 0 2 2 0 4 0 0 0 0 0 0 0
400 0 2 2 0 2 0 0 2 16 0 0 0
800 0 0 0 0 0 0 0 2 0 0 0 0
1600 0 0 0 0 0 0 0 0 0 0 0 0
3200 0 0 0 0 2 0 0 0 0 0 0 0
Total number of dogs 48 48 44 48 48 44 48 48 44 48 48 44
Positive titres are shown in bold
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exposure or differences in immune status could have
affected the vaccine responses of individual dogs in our
study. Accordingly, we observed highly variable vaccine
responses among individual dogs, as also reported in
previous studies [10]. It could be argued that we missed
the maximal MAT titres against the Icterohaemorrha-
giae serogroup, because we sampled the dogs only once
16–31 days after the second immunization, whereas a
previous study followed the MAT titres for several
weeks following immunization [10]. However, Martin
et al. found the highest MAT titres for the vaccine
serovars at weeks 4 and 7 after the start of immunization,
which is similar to the time point used in the present
study to evaluate seroconversion following vaccination.
Importantly, a lack of seroconversion does not imply lack
of immune protection against the vaccine serovar Copen-
hageni. Evaluating the protective potential of Leptospira
vaccines by use of MAT titres does not provide the
entire picture, because previous studies have shown
that post-vaccination titres may not correlate with
protection [11, 34].
Seroconversion following vaccination was also observed
for some non-vaccine serovars, including Autumnalis,
Pomona and Pyrogenes. This finding is not unexpected
and can be explained by cross-reactivity in MAT among
different Leptospira serovars. MAT titres are not serovar-
specific, and also in recent studies, dogs developed posi-
tive titres against non-vaccine serovars following vaccin-
ation with bi- and tetravalent Leptospira vaccines [10–12].
In one study, dogs showed even highest titres to non-
vaccine serovars [12]. In the present study, one dog
showed maximal seroconversion for the non-vaccine sero-
var Autumnalis following vaccination, with a titre of 3200
in MAT, although the titres for all of the vaccine serovars
were negative at that time except for the serovar Canicola
(800). Besides vaccination, natural exposure to the serovar
Autumnalis coinciding with vaccination could have
accounted for seroconversion in this animal. However, the
dog showed no clinical signs or abnormalities in haema-
tology and blood biochemistry compatible with leptospir-
osis at that time. Our results indicate that even high titres
(≥ 800) against non-vaccine serovars should be interpreted
with caution in vaccinated dogs exhibiting signs consistent
with leptospirosis.
Half of the dogs showed positive MAT titres at study
enrolment for the serovar Canicola, although vaccines
containing this serovar had been administered to the
dogs up to 1745 days prior to sampling. The dog is
assumed to be a natural reservoir host of L. interrogans
serovar Canicola, and before the introduction of efficient
vaccines, clinical leptospirosis in dogs has commonly
been associated with this serovar. Because the present
study was performed in privately owned dogs with out-
door access, natural exposure to leptospires in addition
to vaccination could have resulted in antigenic stimulation
in these dogs. Our results are in contrast to an earlier
study that evaluated Leptospira antibodies in privately
owned dogs in Switzerland between 1991 and 1996 [35].
In that study, 34% of the dogs showed positive Leptospira
antibody titres, with seroconversion to other serovars, e.g.,
Bratislava, Australis, Icterohaemorrhagiae, Pomona and
Grippotyphosa, being common. Moreover, in a survey of
259 dogs from Switzerland over a 10-year-period before
the introduction of the tetravalent vaccine, only 12.3% of
the dogs showed seropositivity to serovar Canicola [5].
We cannot conclude from the present data whether the
positive MAT titres to Canicola were due to previous vac-
cination or natural exposure to this serovar. However,
in light of the large time span elapsed since the last
vaccination in some of the seropositive dogs, natural
exposure seems likely, and vaccination against this ser-
ovar can still be advocated.
In the present study, dogs were specifically examined
for evidence of myocarditis due to anecdotal reports of
cardiac changes after vaccination with this new vaccine.
There is some credibility to such a potential association,
because natural infection with leptospirosis may, indeed,
cause myocarditis. Even though clinically important myo-
carditis is rare in dogs and people after natural infection
[6, 36], subclinical myocarditis may be quite commonly
present in both species based on biochemical abnor-
malities, specifically the elevation of cTroponin I [6], and
histopathological findings [7]. Furthermore, myocarditis
has been documented as an adverse event following vac-
cination in humans, such as after smallpox vaccination
[37]. The present study found no echocardiographic, elec-
trocardiographic or biochemical evidence of subclinical
vaccine-induced myocarditis. Based on the limited num-
ber of dogs included in the present study, myocarditis
as a rare complication of leptospirosis vaccination can-
not, however, completely be ruled out.
The present study has some limitations. Due to the
prospective study design, the number of dogs included
in the study was too small to evaluate rare adverse
events induced by the vaccine. This could be assessed by
large retrospective studies and pharmacovigilance data.
The present study also did not follow the course of the
MAT titres after vaccination and therefore cannot evaluate
the time point of maximal MAT titres and the duration of
seropositivity induced by the vaccine. Third, the inclusion
of other vaccine components could have influenced the
clinical and serological response of the dogs. However, we
chose this setting to most accurately mimic the situation
in the field, where Leptospira vaccines are commonly
administered together with other vaccine components
licenced for concurrent administration. Finally, mea-
surements of cTroponin I were only obtained before
the first and 16–31 days after the second vaccination. It
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can be argued that an elevation might have been present
earlier after vaccination. However, the complete absence
of any evidence of morphological, functional and electrical
cardiac abnormalities makes clinically important myocar-
dial damage very unlikely.
Conclusions
The present study indicates that the novel tetravalent
Leptospira vaccine Nobivac® L4 is generally well-
tolerated and that clinical signs following vaccination
were mild and transient. Seroconversion following vac-
cination differed considerably among individual dogs
and among the vaccine serovars. High titres to non-
vaccine serovars were present in some dogs following
vaccination, which hampers the interpretation of single
MAT titres in vaccinated dogs with clinical signs
consistent with leptospirosis. In the light of the high in-
cidence and mortality rate associated with clinical
leptospirosis in dogs in Europe, vaccination with this
tetravalent vaccine can be advocated for every dog with
potential exposure to leptospires.
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